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Previewsa new LPS-triggered phenomenon within
the cytoplasm. This observation also rai-
ses the possibility that regulation of P2X7
sensitivity to ATP might also function in
other circumstances and biological sys-
tems, characterized by P2X7 engagement
in response to apparently low concentra-
tions of ATP.
The mechanism by which P2X7 drives
cytotoxicity is also poorly understood
and will have to be clarified. It needs to
be demonstrated that pore-formation is
sufficient to drive membrane disruption
upon ATP ligation.
Another question remaining in the field
is to understand whether IL-1b release
upon inflammasome activation is a pas-
sive event that relies onmembranedisrup-
tion or an active and regulated mecha-
nism. The fact that upon intracellular LPS
exposure P2X7 deficient macrophages
release IL-1b in absence of pyroptosis
suggests that in some circumstances
IL-1b release can be part of an active pro-
cess. The detailed study of P2X7-deficient
macrophagesmight therefore turn out to a
valuable approach to study possible IL-1b
secretion mechanisms that might occur
independently of cell lysis.
Finally, another caspase-11 substrate,
Gasdermin D, has been identified recently(Kayagaki et al., 2015; Shi et al., 2015). Its
cleaved product has been shown to
initiate a pyroptosis program per se.
However, how it exerts cytotoxic func-
tion remains to be discovered. Future
studies will tell us whether this inflam-
matory caspase substrate co-operates
with pannexin-1 and P2X7 to elicit cell
death or whether it defines an alternative
form of pyroptosis. Similarly, it is unclear
whether caspase-1 mediated pyroptosis
relies on the same substrates as cas-
pase-11. If distinct substrates trigger
different death programs, the question
that might arise is whether these sub-
types of pyroptosis have different in-
flammatory properties.
Pyroptosis-mediated inflammation can
have different outcomes ranging from
healing infections to sepsis and death.
Unlocking the mechanisms regulating
the initiation of pyroptosis are great steps
forward that will bring us on the path to a
better understanding of the physiological
roles of pyroptosis. This will, in the long
run, contribute to the development of
therapeutic strategies aimed at enhancing
the defenses against pathogens and tu-
mors, or when pyroptosis is too strong,
to limit the harmful consequences of
inflammation.Immunity 43, NREFERENCES
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Broadly neutralizing antibodies targeting quaternary epitopes on the apex of the HIV-1 envelope spike are an
attractive vaccine target, yet engineering immunogens that recapitulate such epitopes has proven difficult. In
this issue of Immunity, Andrabi and colleagues (2015) identify an exciting new candidate immunogen that
could initiate the production of these types of antibodies through vaccination.After several years of HIV-1 infection,
subsets of individuals develop broadly
neutralizing antibodies (bnAbs). Ad-
vances in antigen-specific B cell isolation
and single-cell antibody cloning have ledto the characterization of an increasing
number of monoclonal antibodies that
can potently neutralize a wide range
of HIV-1 strains from such subjects.
Passively delivered bnAbs protect againstHIV-1 infection in experimental animal
models, and it is expected that if elicited
by vaccination, they could provide steril-
izing immunity in humans. bnAbs target
four major sites on the HIV-1 envelopeovember 17, 2015 ª2015 Elsevier Inc. 837
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Previewsglycoprotein (Env) spike, one located at
the base of subunit gp41 and three
located in subunit gp120: the CD4 binding
site (CD4-BS), a region centered around a
conserved glycan at position 332 at the
base of the third hypervariable region
(V3), and a region made up of the first
and second Env hypervariable regions
(V1 and V2) at the trimer apex (Burton
and Mascola, 2015). Recently, bnAbs
whose epitopes span gp120 and gp41
were identified. bnAbs that target the
same sites of Env and have similar struc-
tural features are grouped into classes.
Understanding the structural features
and ontogenies of the different class
members not only provides insight into
how the human immune system responds
to infection but also can assist immu-
nogen-design efforts aimed at eliciting
antibodies that target these vulnerable
sites on Env through vaccination.
In this issue of Immunity, the study by
Andrabi et al. (2015) provides important
new information on bnAbs that target the
Env spike’s apex, where the V1 and V2 re-
gions of the three protomers forming the
spike come together to form a canopy.
These ‘‘V2 apex bnAbs’’ are attractive tar-
gets for vaccine development because (1)
they arise in 20%–40% of individuals
who develop bNAbs, demonstrating that
their epitopes are immunogenic and thus
could be elicited in a significant propor-
tion of vaccinated individuals; (2) they
are not as mutated as other types of
bnAbs, so their elicitation might not
require complex and prolonged immuni-
zation regimens; and (3) they emerge
sooner in infection than other types of
bnAbs. However, there has been no clear
strategy to elicit V2 apex bnAbs by immu-
nization. In this study, the authors
examine the binding and neutralizing ac-
tivities of four prototypic V2 apex bnAbs
(PG9, CH01, PGT145, and CAP256.09)
isolated from different donors in an effort
to identify common features that allow
these antibodies to neutralize a diverse
range of HIV-1 strains despite binding to
a highly variable region of Env.
At the V1-V2 apex, these four proto-
typic bnAbs home in on a lysine-rich re-
gion that is largely shielded by conserved
glycans. Although the extensive glycosyl-
ation of Env is thought to limit its recogni-
tion by antibodies, V2 apex bnAbs have
found ways to take advantage of this
sugar coating. Because of their unusually838 Immunity 43, November 17, 2015 ª2015long (R24 aa) CDRH3 regions (9–11 aa in
most antibodies), V2 apex bnAbs are able
to penetrate the glycan shield. In doing so,
they also make direct contact with a wide
range of diverse sugars at positions 160
and 156.
Although the four V2 apex bnAbs exam-
ined target Env in similar ways, they
each evolved independently in different
individuals and have distinct ontogenies.
Two, PG9 and CAP256.09, are derived
from different VH genes, yet they share
99% VH sequence identity. They also
share a D-gene-encoded motif in their
CDRH3; this region is important for bind-
ing and neutralization. The other two,
CH01 and PGT145, are derived from
distinct VH genes whose protein products
diverge at the amino acid level. The light
chains (LCs) of all four antibodies are
unique.
Although the unique features of the
CDRH3 regions of these Abs are crucial
for their neutralizing activities, an impor-
tant observation made by Andrabi et al.
is that VH and VL elements outside of
CDRH3 regions are also involved in
the neutralizing properties of V2 apex
bnAbs, given that engraftment of the
CDRH3 regions of PG9 and CAP256.09
onto antibody heavy chains (HCs)
derived from non-cognate VH genes
leads to loss of neutralizing activity.
One of the most intriguing findings in
the study is that the inferred germline
forms (iGLs) of the bnAbs (reverted
to chromosomally encoded sequence,
except for the CDRH3 region) displayed
neutralizing activities against a subset
of the viruses neutralized by the cor-
responding mutated antibodies. This
neutralization was similarly dependent
on the glycosylation pattern of Env, sug-
gesting that the modes of neutralization
by the iGL antibodies and themutated an-
tibodies are the same.
The observation that the iGLs can
neutralize someHIV-1 viruses is important
from the perspective of eliciting V2 apex
Abs by vaccination. The finding is par-
ticularly interesting because similar
studies conducted with bnAbs that target
different Env vulnerable sites, such as the
CD4-BS or conserved epitopes in V3, re-
vealed that those iGLs do not bind recom-
binant Env or display HIV-1-neutralizing
activities (Hoot et al., 2013; Mouquet
et al., 2012). iGLs presumably represent
the germline B cell receptors that are ex-Elsevier Inc.pressed on naive B cells and are bnAb
progenitors. The fact that the iGL forms
of V2 apex bnAbs can neutralize some
HIV-1 viruses suggests that specifically
designed immunogens that accurately
recapitulate the key structural features of
the V2 apex could stimulate naive V2
apex bnAb progenitors and initiate the
production of these types of antibodies
during vaccination.
Although the mutated V2 apex bnAbs
neutralize diverse HIV-1 viruses, they
display poor reactivity toward soluble
gp120 or gp140 recombinant Env pro-
teins derived from these neutralization-
sensitive viruses. This is because the
epitope recognized by these antibodies
has a quaternary nature, which is very
difficult to stably reproduce on conven-
tional gp120 or gp140 proteins. Here, by
taking advantage of novel approaches to
build stable soluble forms of the HIV-1
Env spike (SOSIP) that present quaternary
epitopes targeted by bnAbs (Sanders
et al., 2013), the authors engineered a
SOSIP protein (CRF02_AG) derived from
one of the viruses that is neutralized by
the iGL forms of PG9, CH01, and
CAP256.09. In doing so, the authors
have generated the first Env mimic that
binds multiple iGL forms of V2 apex
bnAbs (Figure 1). This represents an
exciting first step toward being able to
initiate the process of eliciting V2 apex
bnAbs through vaccination.
A caveat of these studies is that the
CDRH3 sequences of the mutated Abs
were used for engineering the iGL forms.
However, according to next-generation
sequencing of longitudinal samples from
the CAP256 donor (Doria-Rose et al.,
2014), the CRF02_AG SOSIP is also
recognized by the true progenitor of the
CAP256 lineage, which indicates that
this immunogen might select for naive B
cells with long CDRH3 regions capable
of recognizing the V2 apex.
The V2 apex bnAbs are less mutated
than some other classes of bnAbs. For
example, some CD4-BS-specific bnAbs
can be up to up 30% divergent from
germline bnAbs (Georgiev et al., 2013).
In fact, this study reveals that only a small
number of somatic mutations are neces-
sary for achieving significant neutralizing
activity. The authors identified eight HC
mutations that arose independently in
PG9 and CAP256.09. Three of these mu-
tations were also shared by CH01,
Figure 1. Selection Process that Andrabi et al. Used to Identify Novel Immunogens Aimed at Eliciting V2 Apex Broadly Neutralizing HIV-1
Antibodies
Broadly neutralizing antibodies (bnAbs) that target the V1-V2 apex of the HIV-1 envelope protein (Env) were isolated from different HIV-1+ donors. Bioinformatics
was used for inferring the amino acid sequences (except for that of CDRH3) of the germline-encoded bnAb progenitors (iGLs). iGL antibodies were tested
for neutralizing activity against a panel of diverse HIV-1 viruses. Viruses that were neutralized by the majority of iGL antibodies were selected for recombinant
Env production. One Env that successfully recapitulated the structure of the V1-V2 apex was identified by detectable binding to the iGL antibodies.
This recombinant Env could be used as an immunogen to stimulate naive B cells expressing B cell receptors that resemble the iGL antibodies targeting the
V1-V2 apex.
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evolutionary antibody-maturation path-
ways in these distinct antibody lineages.
The introduction of these eight mutations
on the HC of iGL PG9 resulted in an
expansion in the breadth and potency of
neutralization. When eight additional mu-
tations (shared by the LC of the PG9 and
PG16 antibodies) were introduced, the
breadth and potency of neutralization
were further increased to levels ap-
proaching those of the fully mutated anti-
bodies. Thus, although extensive somatic
hypermutation in both the HC and LC
might be required for substantial neutral-
izing activity in bnAbs that bind the CD4-
BS (Dosenovic et al., 2015; Klein et al.,
2013), V2 apex bnAbs might be able to
achieve significant neutralizing activities
with a relatively small number of somatic
hypermutations that might be more
easily induced with current vaccination
protocols.
Finally, it is worth noting the iGL and
mutated forms of the V2 apex bnAbsstudied here do not display autoreactivity,
a property associated with other types of
bnAbs and with antibodies with long
CDRH3 regions. This could lead to the
elimination of bnAb progenitor B cells
during their development (Mascola and
Haynes, 2013).
In summary, this study provides infor-
mation that strongly suggests that during
chronic HIV-1 infection, Env variants with
particular structural features emerge to
bind and activate naive B cells expressing
B cell receptors with particular CDRH3 re-
gions uniquely poised to penetrate the
V1-V2-associated glycan shield at the
apex of the Env spike. Furthermore, it
is revealed that a relatively small number
of somatic hypermutations shared by
different V2 apex bnAbs are sufficient for
improving the neutralizing activities of
these antibodies. The design of a recom-
binant Env protein that binds the inferred
germline forms of V2 apex bnAbs is
certainly an exciting advance in the field
and will now permit the experimentalImmunity 43, Nvalidation of the immunization regiments
proposed in this study to elicit V2 apex
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Parasitic helminths are potent regulators of host immunity, including inhibition of allergic inflammation. In this
issue of Immunity, Zaiss et al. (2015) reveal that microbiota compositional shifts during helminth infection
contribute to the multifaceted ways that helminths modulate host immunity.The primary goal for a parasite is to
remain within their host for as long as
possible, while finding ways to propa-
gate. There is little doubt that helminths
are successful in achieving this goal, as
demonstrated by their ability to mount
chronic infections in mammalian hosts.
Approximately two billion people world-
wide are currently infected with hel-
minths; many infections last for several
years, and some even persist for de-
cades. The success of these parasites
is attributed to their capacity to modulate
host immune responses, which helps
their continued colonization and prevents
their expulsion. The immunomodulatory
capabilities of helminths have a broad
scope, extending to suppression of im-
mune responses against foreign antigens
and allergens. Thus, helminths or hel-
minth excretory-secretory products have
the potential to be used therapeutically
in the treatment of allergic diseases
(McSorley et al., 2013). Given that hel-
minth infection alters the composition of
the bacterial intestinal microbiota (Rey-
nolds et al., 2015) and that the microbiota
composition has been implicated in influ-
encing allergic disease (McCoy and Ko¨l-
ler, 2015), a major unanswered question
is: to what extent does helminth infectionreduce allergic inflammation through ef-
fects on the microbiota?
In this issue of Immunity, Zaiss et al.
(2015) present evidence that one pathway
by which helminth infection dampens
allergic inflammation occurs as a result
of compositional shifts within the intesti-
nal microbiota. First, they have shown
that infectingmicewith the intestinal nem-
atode parasite Heligmosomoides polygy-
rus reduced airway inflammation in a
house dust mite (HDM)-induced model
of allergy, consistent with previous re-
ports of helminths suppressing allergy
(McSorley et al., 2013). Next, Zaiss et al.
(2015) reported the striking observation
that the helminth-induced protection
from airway inflammation is abrogated in
mice that had been given antibiotics, sug-
gesting that the intestinal microbiota is
required for suppression of airway inflam-
mation. Importantly, antibiotic treatment
did not affect H. polygyrus numbers.
Moreover, co-housing with H. polygyrus-
infected mice, or transferring cecal con-
tents from H. polygyrus-infected mice to
uninfected recipients, resulted in protec-
tion from HDM-induced inflammation.
The authors confirmed that H. polygyrus
infection was unable to be transferred to
recipient mice during these experiments,suggesting that a transferable component
of the helminth-modified microbiota was
able to provide protection from airway
inflammation.
Compositional shifts within the intesti-
nal bacterial microbiota have been previ-
ously associated with susceptibility to
allergic disease, after alterations in diet
or the administration of antibiotics
(McCoy and Ko¨ller, 2015). How could mi-
crobiota shifts during helminth infection
contribute to reduced airway inflamma-
tion? Zaiss et al. (2015) show that
H. polygyrus-infected mice, or mice
receiving a H. polygyrus-modulated mi-
crobiota, had elevated cecal amounts
of short chain fatty acids (SCFA). They
demonstrated that H. polygyrus itself
was capable of generating the SCFA ace-
tate in in vitro cultures (Zaiss et al., 2015).
Indeed, several other helminth species
have been shown to produce acetate
(Tielens et al., 2010). Because antibi-
otic-treated H. polygyrus-infected mice
showed completely abrogated SCFA pro-
duction, it is likely that the major source of
SCFA generated during H. polygyrus
infection was the bacterial microbiota,
rather than the parasites themselves
(Zaiss et al., 2015). They further demon-
strated that elevated SCFA levels are a
